| Literature DB >> 28461531 |
Alexis Ogdie1,2, Maarten de Wit3,4, Kristina Callis Duffin3,4, Willemina Campbell3,4, Jeffrey Chau3,4, Laura C Coates3,4, Lihi Eder3,4, Musaab Elmamoun3,4, Oliver FitzGerald3,4, Dafna D Gladman3,4, Niti Goel3,4, Jana James3,4, Umut Kalyoncu3,4, John Latella3,4, Chris Lindsay3,4, Philip J Mease3,4, Denis O'Sullivan3,4, Ingrid Steinkoenig3,4, Vibeke Strand3,4, William Tillett3,4, Ana-Maria Orbai3,4.
Abstract
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) Core Set working group recently published the updated 2016 psoriatic arthritis (PsA) core domain set, a set of disease features that should be measured in all clinical trials. At the GRAPPA annual meeting in July 2016, the PsA working group presented the updated PsA core domain set endorsed by 90% of participants at OMERACT in May 2016 and drafted a roadmap for the development of the PsA core outcome measurement set. In this manuscript, we review the development process of the PsA core domain set and the ongoing and proposed work streams for development of a PsA core measurement set.Entities:
Keywords: GRAPPA; OMERACT; OUTCOME MEASURES; PSORIASIS; PSORIATIC ARTHRITIS
Mesh：
Substances：
Year: 2017 PMID： 28461531 PMCID： PMC5605807 DOI： 10.3899/jrheum.170150
Source DB: PubMed Journal: J Rheumatol ISSN： 0315-162X Impact factor: 4.666